Want to see HK:1931 full AI Analyst Report?
1931 Stock Chart & Stats
HK$3.85
HK$0.05(2.67%)
At close: 4:00 PM EST
HK$3.85
HK$0.05(2.67%)
Day’s Range― - ―
52-Week RangeHK$0.56 - HK$12.86
Previous CloseN/A
Volume18.00K
Average Volume (3M)1.48M
Market Cap
HK$1.02B
Enterprise ValueHK$2.33B
Total Cash (Recent Filing)HK$551.05M
Total Debt (Recent Filing)HK$1.93B
Price to Earnings (P/E)25.4
Beta0.57
Next Earnings
Aug 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.81%
Share Statistics
EPS (TTM)0.02
Shares Outstanding1,621,488,000
10 Day Avg. Volume1,443,300
30 Day Avg. Volume1,483,483
Financial Highlights & Ratios
PEG Ratio-1.25
Price to Book (P/B)1.29
Price to Sales (P/S)1.35
P/FCF Ratio-3.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Historical Margin Track RecordA multi-year run of healthy operating margins and positive growth through 2021–2024 shows the business model and cost base can generate durable profitability. That track record implies management and operations can restore operating leverage if revenue stabilizes, supporting medium-term recovery.
Sizable Equity BufferA substantial equity base provides a capital cushion against the 2025 earnings shock and supports borrowing capacity. This persistent equity buffer helps absorb losses, reduces insolvency risk, and preserves optionality for restructuring or strategic investment over the next several quarters.
Established Medical-distribution FranchiseOperating in medical distribution is structurally defensive with recurring demand from healthcare providers. An established employee base (~863) and industry positioning support operational continuity and customer relationships, providing durable revenue channels if macro pressure eases.
Bears Say
Severe Cash-flow CollapseA deep swing to roughly -919M OCF and -1.01B FCF materially weakens internal funding, raises near-term liquidity and refinancing risk, and forces reliance on external capital. Sustained negative cash generation undermines investment capacity and elevates solvency concerns over months.
Revenue And Margin DeteriorationAn ~11% revenue decline alongside a collapse in net margin to ~1.2% indicates weakening pricing power or cost pressure. Reduced profitability erodes internal capital formation and ROE, making sustained operational recovery harder without structural fixes or revenue restoration.
Rising Leverage And Reduced FlexibilityDebt-to-equity rising to ~0.62 from ~0.20 meaningfully increases financial risk and interest burden. Higher leverage reduces strategic flexibility, raises covenant and refinancing exposure, and magnifies downside in prolonged weakness, limiting capacity to invest or pursue restructuring.
IVD Medical Holding Limited News
1931 FAQ
What was IVD Medical Holding Limited’s price range in the past 12 months?
IVD Medical Holding Limited lowest stock price was HK$0.56 and its highest was HK$12.86 in the past 12 months.
What is IVD Medical Holding Limited’s market cap?
IVD Medical Holding Limited’s market cap is HK$1.02B.
When is IVD Medical Holding Limited’s upcoming earnings report date?
IVD Medical Holding Limited’s upcoming earnings report date is Aug 14, 2026 which is in 38 days.
How were IVD Medical Holding Limited’s earnings last quarter?
IVD Medical Holding Limited released its earnings results on Mar 27, 2026. The company reported -HK$0.003 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.003.
Is IVD Medical Holding Limited overvalued?
According to Wall Street analysts IVD Medical Holding Limited’s price is currently Overvalued.
Does IVD Medical Holding Limited pay dividends?
IVD Medical Holding Limited pays a Notavailable dividend of HK$0.062 which represents an annual dividend yield of 3.81%. See more information on IVD Medical Holding Limited dividends here
What is IVD Medical Holding Limited’s EPS estimate?
IVD Medical Holding Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does IVD Medical Holding Limited have?
IVD Medical Holding Limited has 1,621,488,000 shares outstanding.
What happened to IVD Medical Holding Limited’s price movement after its last earnings report?
IVD Medical Holding Limited reported an EPS of -HK$0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.893%.
Which hedge fund is a major shareholder of IVD Medical Holding Limited?
Currently, no hedge funds are holding shares in HK:1931
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
IVD Medical Holding Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
320.00%
12-Months-Change
Fundamentals
Return on Equity
1.09%
Trailing 12-Months
Asset Growth
12.45%
Trailing 12-Months
Company Description
IVD Medical Holding Limited
IVD Medical Holding Limited functions as an investment holding company primarily engaged in the distribution of in vitro diagnostic (IVD) products. Its operations span both Mainland China and global markets. The enterprise structures its activities into three key segments: a Distribution Business, Maintenance Services, and a Self-branded Products Business. The company offers a comprehensive range of IVD analysers, reagents, and other consumables. These are utilized across various diagnostic testing fields, including hematology and body fluid analysis, immunoassay, clinical chemistry, molecular diagnostics, microbiology, and point-of-care testing. Additionally, it supplies haemostasis products and provides specialized solution services for clinical laboratories within hospitals. Its maintenance services include repair, installation, and training for end customers. Under its proprietary IVD brand, the company actively researches, develops, manufactures, and markets IVD analyzers and reagents. Its clientele encompasses hospitals, various healthcare institutions, logistics partners, and independent distributors. Established in 1993, IVD Medical Holding Limited maintains its headquarters in Shanghai, People's Republic of China.
Technical Analysis
China Health Group
―
Shanghai Pharmaceuticals Holding Co
―
Sinopharm Group Co
―
Medlive Technology Co., Ltd.
―
Charmacy Pharmaceutical Co., Ltd. Class H
―
Options Prices
Currently, No data available
---